Molecular Biology Reports

, Volume 40, Issue 9, pp 5397–5405 | Cite as

Cancer targeting gene-viro-therapy for pancreatic cancer using oncolytic adenovirus ZD55-IL-24 in immune-competent mice



Cancer targeting gene-viro-therapy (CTGVT) may prove to be an effective treatment for pancreatic cancer (PC). This study was intended to explore the anti-tumor effect of ZD55-IL-24 (oncolytic adenovirus ZD55 harboring IL-24) on PC in immune-competent mice. The expression of gene harbored by oncolytic adenovirus ZD55 in PC cells was detected by reporter-gene assays. The in vitro anti PC ability of ZD55-IL-24 was tested by MTT, crystal violet staining and apoptosis assays. The in vivo anti PC effect of ZD55-IL-24 was further observed in an immune-competent mice model by detecting anti-tumor immunity and induction of apoptosis. The expression of gene harbored by ZD55 in PC cells was significantly higher than that harbored by the replicated-deficient adenovirus, and the amount of gene expression was time-dependent and dose-dependent. Both ZD55-IL-24 and ZD55 inhibited PC cells growth, but the anti-tumor effect of ZD55-IL-24 was significantly stronger than that of ZD55, and the ability of ZD55-IL-24 in inducing PC apoptosis was significantly stronger than that of ZD55. The tumor-forming rate of group ZD55-IL-24 was the lowest, and the tumor-growing rate was also significantly lower than that of group ZD55 in immune-competent PC models. Moreover, ZD55-IL-24 mediated more anti-cancer immunity effects by induction of stronger T-lymphocytes response to PC cells, higher levels of γ-IFN and IL-6 cytokines. ZD55-IL-24-mediated CTGVT could inhibit PC growth not only by inducing oncolysis and apoptosis but enhancing the anti-cancer immune effects by inducing T cell response to PC and up-regulating γ-IFN and IL-6 cytokine in immune-competent mice. This may serve as a candidate therapeutic approach for the treatment of PC.


CTGVT Oncolytic adenovirus ZD55-IL-24 Pancreatic cancer Immune-competent 



This work was supported by the National Natural Science Foundation of China (81001007, 81270003, 31100639); the Program for Young Excellent Talents in Tongji University (2008KJ060); and Youth Fund of Shanghai 10th People’s Hospital (10RQ105).


  1. 1.
    Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA: a cancer journal for clinicians 60(5):277–300CrossRefGoogle Scholar
  2. 2.
    Tong D, Zhou Y, Chen W, Deng Y, Li L, Jia Z, Qi D (2012) T cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and susceptibility to pancreatic cancer. Mol Biol Rep 39(11):9941–9946PubMedCrossRefGoogle Scholar
  3. 3.
    Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY, Qian QJ, Liu XY (2003) An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res 13(6):481–489PubMedCrossRefGoogle Scholar
  4. 4.
    Mahoney DJ, Stojdl DF (2012) Fighting fire with fire: rewiring tumor cells for oncolytic virotherapy. Future Oncol 8(3):219–221PubMedCrossRefGoogle Scholar
  5. 5.
    Bais S, Bartee E, Rahman MM, McFadden G, Cogle CR (2012) Oncolytic virotherapy for hematological malignancies. Adv Virol 2012:186512PubMedGoogle Scholar
  6. 6.
    Patil SS, Gentschev I, Nolte I, Ogilvie G, Szalay AA (2012) Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients. J Transl Med 10:3PubMedCrossRefGoogle Scholar
  7. 7.
    Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274(5286):373–376PubMedCrossRefGoogle Scholar
  8. 8.
    O’Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Kunich J, Shen Y, Habets G, Ginzinger D, McCormick F (2004) Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6(6):611–623PubMedCrossRefGoogle Scholar
  9. 9.
    Gupta P, Su ZZ, Lebedeva IV, Sarkar D, Sauane M, Emdad L, Bachelor MA, Grant S, Curiel DT, Dent P, Fisher PB (2006) mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther 111(3):596–628PubMedCrossRefGoogle Scholar
  10. 10.
    Chang S, Yang J, Chen W, Xie Y, Sheng W (2011) Antitumor activity of an adenovirus harboring human IL-24 in colon cancer. Mol Biol Rep 38(1):395–401PubMedCrossRefGoogle Scholar
  11. 11.
    Lebedeva IV, Su ZZ, Vozhilla N, Chatman L, Sarkar D, Dent P, Athar M, Fisher PB (2008) Mechanism of in vitro pancreatic cancer cell growth inhibition by melanoma differentiation-associated gene-7/interleukin-24 and perillyl alcohol. Cancer Res 68(18):7439–7447PubMedCrossRefGoogle Scholar
  12. 12.
    Lebedeva IV, Sarkar D, Su ZZ, Gopalkrishnan RV, Athar M, Randolph A, Valerie K, Dent P, Fisher PB (2006) Molecular target-based therapy of pancreatic cancer. Cancer Res 66(4):2403–2413PubMedCrossRefGoogle Scholar
  13. 13.
    Liu XY, Li HG, Yang DQ, Gu JF (2011) Strategy of cancer targeting gene-viro-therapy (CTGVT)—a trend in both cancer gene therapy and cancer virotherapy. Curr Pharm Biotechnol 13(9):1761–1767CrossRefGoogle Scholar
  14. 14.
    Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L, Wang Y, Zhang J, Zhang Z, Huiwang J, Qian Q, Qian C, Liu X (2005) Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther 16(7):845–858PubMedCrossRefGoogle Scholar
  15. 15.
    Qian W, Liu J, Tong Y, Yan S, Yang C, Yang M, Liu X (2008) Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. Leukemia 22(2):361–369PubMedCrossRefGoogle Scholar
  16. 16.
    Yang C, Tong Y, Ni W, Liu J, Xu W, Li L, Liu X, Meng H, Qian W (2010) Inhibition of autophagy induced by overexpression of mda-7/interleukin-24 strongly augments the antileukemia activity in vitro and in vivo. Cancer Gene Ther 17(2):109–119PubMedCrossRefGoogle Scholar
  17. 17.
    Zhong S, Yu D, Wang Y, Qiu S, Wu S, Liu XY (2010) An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer. Acta Oncol 49(1):91–99PubMedCrossRefGoogle Scholar
  18. 18.
    Jiang G, Zhang L, Xin Y, Pei DS, Wei ZP, Liu YQ, Zheng JN (2012) Conditionally replicating adenoviruses carrying mda-7/IL-24 for cancer therapy. Acta Oncol 51(3):285–292PubMedCrossRefGoogle Scholar
  19. 19.
    Kanai R, Rabkin SD, Yip S, Sgubin D, Zaupa CM, Hirose Y, Louis DN, Wakimoto H, Martuza RL (2012) Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst 104(1):42–55PubMedCrossRefGoogle Scholar
  20. 20.
    Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP Jr, Schabel FM Jr (1984) Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 44(2):717–726PubMedGoogle Scholar
  21. 21.
    Xu B, Zheng WY, Jin DY, Wang DS, Liu XY, Qin XY (2012) Treatment of pancreatic cancer using an oncolytic virus harboring the lipocalin-2 gene. Cancer 118(21):5217–5226PubMedCrossRefGoogle Scholar
  22. 22.
    Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Robertson T, Je JE, Lee YS, Parato K, Diallo JS, Fenster A, Daneshmand M, Bell JC, Kirn DH (2011) Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477(7362):99–102PubMedCrossRefGoogle Scholar
  23. 23.
    Schmitt CA (2011) Immunotherapy: seek and destroy: oncolytic virus shows promise in phase I trial. Nat Rev Clin Oncol 8(11):630PubMedCrossRefGoogle Scholar
  24. 24.
    Mohyeldin A, Chiocca EA (2012) Gene and viral therapy for glioblastoma: a review of clinical trials and future directions. Cancer J 18(1):82–88PubMedCrossRefGoogle Scholar
  25. 25.
    Melcher A, Parato K, Rooney CM, Bell JC (2011) Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 19(6):1008–1016PubMedCrossRefGoogle Scholar
  26. 26.
    Cunningham CC, Chada S, Merritt JA, Tong A, Senzer N, Zhang Y, Mhashilkar A, Parker K, Vukelja S, Richards D, Hood J, Coffee K, Nemunaitis J (2005) Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol Ther 11(1):149–159PubMedCrossRefGoogle Scholar
  27. 27.
    Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, Netto G, Rich D, Mhashilkar A, Parker K, Coffee K, Ramesh R, Ekmekcioglu S, Grimm EA, van Hood Wart J, Merritt J, Chada S (2005) Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther 11(1):160–172PubMedCrossRefGoogle Scholar
  28. 28.
    Dash R, Bhutia SK, Azab B, Su ZZ, Quinn BA, Kegelmen TP, Das SK, Kim K, Lee SG, Park MA, Yacoub A, Rahmani M, Emdad L, Dmitriev IP, Wang XY, Sarkar D, Grant S, Dent P, Curiel DT, Fisher PB (2010) mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine Growth Factor Rev 21(5):381–391PubMedCrossRefGoogle Scholar
  29. 29.
    Dent P, Yacoub A, Hamed HA, Park MA, Dash R, Bhutia SK, Sarkar D, Wang XY, Gupta P, Emdad L, Lebedeva IV, Sauane M, Su ZZ, Rahmani M, Broaddus WC, Young HF, Lesniak MS, Grant S, Curiel DT, Fisher PB (2010) The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol Ther 128(2):375–384PubMedCrossRefGoogle Scholar
  30. 30.
    Su Z, Lebedeva IV, Gopalkrishnan RV, Goldstein NI, Stein CA, Reed JC, Dent P, Fisher PB (2001) A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc Natl Acad Sci USA 98(18):10332–10337PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.Department of Anesthesiology and SICUXinhua Hospital, Shanghai Jiaotong University School of MedicineShanghaiChina
  2. 2.Department of Hepatobiliary-Pancreatic SurgeryShanghai Tenth People’s Hospital, Tongji University School of MedicineShanghaiChina
  3. 3.Department of General Surgery6th People’s Hospital of Shanghai, Shanghai Jiaotong UniversityShanghaiChina
  4. 4.Institute of Biochemistry and Cell BiologyShanghai Institutes for Biological Sciences, Chinese Academy of SciencesShanghaiChina

Personalised recommendations